🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD NYU Langone Health joins Tian Zhang, MD, MHS UT Southwestern Medical Center discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no

Highlighting this The PCCTC and DCI Center for Prostate & Urologic Cancers trial of a novel CTLA engaging IO plus Lu177-PSA-617 therapy in men with mCRPC at #ASCO25 #MedIQASCO25 with Tian Zhang, MD, MHS . Clear activity and safe!

Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD NYU Langone Health joins Tian Zhang, MD, MHS UT Southwestern Medical Center discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no

💯- the NCTN is complex but our trials are asking — and answering — many highly relevant questions for everyone that industry is not incentivized to answer. Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network NRG Oncology Children’s Oncology Group Nice editorial Ted Hong Thomas George, MD, FACP, FASCO academic.oup.com/jnci/advance-a…

📺 Watch Tian Zhang, MD, MHS’s recent update on the PDIGREE trial, including new information on tolerability, treatment response, and radiographic response patterns to first-line ipi/nivo for patients with metastatic ccRCC: buff.ly/bFjV3Y7

In company w fantastic Hematology & Oncology Women Physicians Group—HOWPG who have moved and shaped our fields. I post ASCO to share the newest data & impact for our patients. Will continue to do so here & on Bluesky. Appreciate the PR LARVOL!

Thanks Pedro C Barata, MD MSc FACP UroToday.com for featuring our first presentation of #PDIGREE - hope this will be first of many from our adaptive phase 3 trial. ASCO

Nice tutorial on cumulative vs conditional probability for disease recurrence in adjuvant setting! KCCure Kidney Cancer

Proud of our UTSW Simmons Cancer Center clinical research teams displaying our cancer center’s ongoing work in clinical trials Association of American Cancer Institutes #CRI25 meeting today! Clinical trials are essential to improving outcomes for our patients with cancer - here to network & learn best practices!

PEACE-3: Enzalutamide + Radium-223 improved rPFS (19.4 vs 16.4 mo) and OS (42.3 vs 35.0 mo) in mCRPC with bone mets. ⚠️Fracture risk ⬆️ BUT mandatory bone-targeting agents ⬇️ it. tombal silke gillessen Advanced Prostate Cancer Consensus Conference ESMO - Eur. Oncology Annals of Oncology OncoAlert

Full IIT panel at Association of American Cancer Institutes #CRI25 meeting! Nice job from UTSW Simmons Cancer Center multisite IIT guru #KellyKyle! Good to share best practices on good design, funding, and implementation of IITs.

Phase I trial combines ONC-392 with Lutetium-177 for #ProstateCancer. David Wise, MD, PhD NYU Langone Health joins Tian Zhang, MD, MHS UT Southwestern Medical Center discussing this phase I trial of ONC-392 + 177Lu-PSMA, targeting Tregs to overcome resistance after lutetium therapy. Early results: safe, no

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. Brian Rini, MD OncoAlert